Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Latest action · Jan 10, 2019 Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 10.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJan 8, 2019
- Passed HouseJan 8, 2019
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
This bill (1) reauthorizes, revises, and establishes several programs and entities relating to public-health emergency preparedness and response; and (2) addresses the approval process for over-the counter (OTC) drugs.
Among other programs, the bill reauthorizes through FY2023 and revises
- the Public Health Emergency Preparedness cooperative-agreement program administered by the Centers for Disease Control and Prevention (CDC),
- the Hospital Preparedness Program,
- the CDC situational-awareness and biosurveillance program,
- the Emergency System for Advance Registration of Volunteer Health Professionals,
- the National Disaster Medical System,
- the Volunteer Medical Reserve Corps,
- the National Advisory Committee on Children and Disasters,
- the Strategic National Stockpile, and
- the Biomedical Advanced Research and Development Authority.
In addition, the bill provides statutory authority for existing programs, including the CDC's Children's Preparedness Unit and the Public Health Emergency Medical Countermeasures Enterprise. The bill also establishes new programs and entities, including a trauma-center grant program to support military trauma teams.
The bill further modifies the approval process for OTC drugs by providing statutory authority for the Food and Drug Administration (FDA) to (1) regulate certain OTC drugs that are marketed without an approved new-drug application, and (2) issue administrative orders specifying the conditions under which an OTC drug may be deemed safe and effective and not subject to approval as a new drug. The FDA must assess and collect user fees for OTC drugs, including OTC-drug facility and OTC-drug order-request fees.
Recorded votes 1
Newest first. Open one to see how every member voted.
Cosponsors 7
Members who signed on, in the order they did. All signed on Jan 8, 2019.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-KY | Brett Guthrie | Original | Jan 8, 2019 |
| D-MI | Debbie Dingell | Original | Jan 8, 2019 |
| D-CO | Diana DeGette | Original | Jan 8, 2019 |
| D-NJ | Frank Pallone, Jr. | Original | Jan 8, 2019 |
| R-OR | Greg Walden | Original | Jan 8, 2019 |
| R-OH | Robert E. Latta | Original | Jan 8, 2019 |
| R-IN | Susan W. Brooks | Original | Jan 8, 2019 |
Committees 4
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jan 8, 2019 |
| House | Homeland Security Committee | Referred Jan 8, 2019 |
| House | Veterans' Affairs Committee | Referred Jan 8, 2019 |
| House | Judiciary Committee | Referred Jan 8, 2019 |
Actions 11
Everything that happened, newest first.
- Jan 10, 2019Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 10.
- Jan 9, 2019Received in the Senate. Read the first time. Placed on Senate Legislative Calendar under Read the First Time.
- Jan 8, 2019Introduced in House
- Jan 8, 2019Referred to the Committee on Energy and Commerce, and in addition to the Committees on Homeland Security, Veterans' Affairs, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Jan 8, 2019Mr. Pallone moved to suspend the rules and pass the bill.
In the Congressional Record 4
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| Senate | Notices S1910Intention to object to H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act: Senator Braun | Mike Braun R-IN | Mar 14, 2019 |
| Senate | Debate and remarks S111 | Mitch McConnell R-KY | Jan 10, 2019 |
| Senate | Debate and remarks S106 | Mitch McConnell R-KY | Jan 9, 2019 |
| House | Debate and remarks H237–H266Text printed H237–H262Recorded votes H275 | Anna G. Eshoo D-CA, Brett Guthrie R-KY, Debbie Dingell D-MI, Frank Pallone, Jr. D-NJ, Michael C. Burgess R-TX, Robert E. Latta R-OH, Sheila Jackson Lee D-TX, Susan W. Brooks R-IN | Jan 8, 2019 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 3, January 8, 2019, page H285.
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46319 | Novel Coronavirus 2019 (COVID-19): Q&A on Global Implications and Responses Archived | Report | May 14, 2020 |
Related bills 5
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 11 | Strengthening the National Disaster Medical System Act of 2019 | Related bill | Jan 3, 2019 |
| HR 345 | SMASH Act | Related bill | Jan 25, 2019 |
| S 1379 | Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 | Related bill | Jun 24, 2019 |
| S 2740 | Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 | Related bill | Dec 14, 2019 |
| HR 3443 | To clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. | Related bill | Jul 24, 2019 |
Titles 6
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes.
- Short Titles as Passed House for portions of this bill
- Over-the-Counter Monograph User Fee Act of 2019
- Short Title(s) as Passed House
- Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
- Short Title(s) as Passed House for portions of this bill
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
- Short Titles for portions of this bill from PCS (Placed on Senate Calendar) bill text
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
- Short Title(s) from PCS (Placed on Senate Calendar) bill text
- Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Advanced technology and technological innovations
- Advisory bodies
- Aging
- Blood and blood diseases
- Border security and unlawful immigration
- Centers for Disease Control and Prevention (CDC)
- Chemical and biological weapons
- Child health
- Child safety and welfare
- Computer security and identity theft
- Congressional oversight
- Consumer affairs
- Disability and paralysis
- Disaster relief and insurance
- Drug safety, medical device, and laboratory regulation
- Emergency communications systems
- Emergency medical services and trauma care
- Emergency planning and evacuation
- Environmental health
- First responders and emergency personnel
- Food and Drug Administration (FDA)
- General health and health care finance matters
- Genetics
- Government employee pay, benefits, personnel management
- Government information and archives
- Government liability
- Hazardous wastes and toxic substances
- Health
- Health facilities and institutions
- Health information and medical records
- Health personnel
- Health programs administration and funding
- Health promotion and preventive care
- Health technology, devices, supplies
- Homeland security
- Hospital care
- Immunology and vaccination
- Infectious and parasitic diseases
- Infrastructure development
- Intelligence activities, surveillance, classified information
- Intergovernmental relations
- Judicial review and appeals
- Licensing and registrations
- Marketing and advertising
- Medical research
- Military medicine
- Minority health
- Musculoskeletal and skin diseases
- Natural disasters
- Performance measurement
- Prescription drugs
- Research and development
- Social work, volunteer service, charitable organizations
- State and local government operations
- Technology assessment
- Terrorism
- User charges and fees
- Veterinary medicine and animal diseases
- Women's health
- World health
Text 2
Each version as it was printed, newest first.
- Jan 10, 2019Placed on Calendar Senate
- Jan 8, 2019Engrossed in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
